Patent intelligence · US
US 12053513
Cancer-specific T-cell receptors
Cancer-specific T-cell receptors
Patent details — US 12053513
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2024
- Expiration
- Aug 1, 2044
- Claims
- 19
- CPC classes
- A61K, A61K2039/5158, A61K2039/70, A61K38/00
Quick answer
US 12053513 (Cancer-specific T-cell receptors) is held by University College Cardiff Consultants Limited. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/5158, A61K2039/70, A61K38/00, A61K38/08, A61K39/0011
More from University College Cardiff Consultants Limited
Related pharmaceutical patents in our USPTO index.
-
US 12383540
Compounds that modulates AMPA receptor function
granted -
US 12318418
Modified adenoviruses
granted -
US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
granted -
US 11850264
Gamma delta T-cell receptor and its ligand
granted -
US 11725039
α/β t-cell receptor and methods of using it
granted
Frequently asked questions
What is US patent 12053513?
US 12053513 (Cancer-specific T-cell receptors) is held by University College Cardiff Consultants Limited. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12053513?
University College Cardiff Consultants Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 12053513 expire?
Our index shows an expiration date of Aug 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.